C4 THERAPEUTICS
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise diseas... e-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
C4 THERAPEUTICS
Industry:
Health Diagnostics Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.c4therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
617 588 6114
Email Addresses:
[email protected]
Total Funding:
273.8 M USD
Technology used in webpage:
SPF EasyDNS EasyDNS Mail
Similar Organizations
RC21X
RC21X is an advanced brain health and performance measurement system.
Reduced
Reduced develops natural flavor enhancers from upcycled produce.
Ravata Solutions
Ravata is enabling production scale embryo engineering.
Nanophase Technologies
Nanophase Technologies Corporation provides nano-engineered solutions for various industrial product applications.
Nectero Medical
Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
Neuro3 Therapeutics
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.
Veramarx Inc.
Veramarx offers the only accurate diagnostic test for early-stage Lyme disease, which is one of the fastest growing infectious diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Genio Technologies, Inc.
MS Pen Technologies specializes in the application of the MasSpec Pen, a novel probe which enables real-time biochemical analysis.
miDiagnostics
miDiagnostics is developing a next-generation diagnostic platform based on a silicon nanofluidic processor.
Matrixome
Matricome develops regenerative medicines by disseminating laminin E8 fragment technology.
Mindshare Medical
Mindshare Medical is revolutionizing how images are used in medicine through analytics
Mediagnost
Mediagnost develops, produces and sells high quality diagnostics for research and clinical practice.
MindPortal
MindPortal makes wearable devices for brain analysis and assessment.
MEDOVEX
MEDOVEX’s management team and board of directors are highly experienced healthcare professionals in all functional areas
Laronde
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
LabCentral
LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at
ActiTrexx GmbH
ActiTrexx GmbH is a stem cell transplantation center that offers curative and cellular therapies.
Aminex Therapeutics
Aminex Therapeutics develops small molecule based cancer treatment solutions.
Alivas
Alivas is a medical company that develops new therapeutic medical devices for refractory constipation.
Axonics Modulation Technologies
Axonics Modulation Technologies is a pre-revenue company developing novel implantable neuromodulation.
ADC Therapeutics
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
Aligos Therapeutics
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
ARCA biopharma
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases.
Active Layer Parametrics
We have developed a system to rapidly and accurately measure mobility and activated carrier concentration profiles
Akadeum Life Sciences
Akadeum develops bioseparation products to facilitate the removal of target cells from biological samples.
Early Detection
Early Detection develops non-invasive and accurate screening tests for an abnormal sugar molecule expressed only in cancer.
Efferon LPS
The Efferon company develops devices with polymer sorbents that help purify the blood during severe conditions of patients with COVID-19
Evincis Bio
Evincis Bio is a company solving therapeutic challenges in Urology with innovative medical technologies.
Enterprise Therapeutics
A UK-based developer of drugs to treat respiratory diseases
electroCore
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
Evon Medics
Evon Medics, LLC is focused on developing and delivering breakthrough therapeutics and devices to address brain-related conditions.
Biop-Medical
Focused on the development of next-generation diagnostics for identifying cancer in epithelial cells.
Bold Diagnostics
Medical device startup developing a diagnostic platform for blood pressure monitoring utilizing a novel parameter
Brightlamp
Brightlamp creates B2B SaaMD for mobile devices to monitor brain injury and disease through pupillary activity.
Breathe Technologies
Breathe Technologies provide healthcare providers and patients with respiratory therapies that optimize breathing and mobility.
Blue Note Therapeutics
Blue Note Therapeutics is a prescription digital therapeutics company that merges deep scientific and clinical expertise.
BEAT BioTherapeutics
BEAT BioTherapeutics develops novel therapies for heart diseases.
Biodol Therapeutics
Biodol Therapeutics made a breakthrough discovery on the origin and maintenance of NP.
Fluid-Screen
Fluid-Screen providees chip technology for bacterial capture.
Tellus Therapeutics
Tellus Therapeutics develops novel small molecules derived from human maternal breast milk.
Tempo Therapeutics
Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Janux Therapeutics
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
UPPER
UPPER is a biomedicine manufacturing company.
1E Therapeutics
1E Therapeutics is a breakthrough, drug development company.
Silarus Therapeutics
Silarus Therapeutics is developing therapeutics targeting erythroferrone
SAGE Therapeutics
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions.
Sapheneia
Sapheneia specializes in diagnostic and analytical image enhancement systems for medical and scientific applications.
Synendos Therapeutics
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.
Diagnovus
Diagnovus is a molecular diagnostics lab providing individualized genetic info. fundamentally changing the way physicians treat patients.
DFusion
DFusion is the developer of the intelligent diagnostic system.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Duke Human Vaccine Institute
DHIV develops novel vaccines and therapeutics and diagnosis for t infectious diseases that impact global health.
AvantGuard
AvantGuard is developing the next generation of antimicrobial products to provide long lasting protection against pathogens
Heartseed
Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine”.
Inhibikase Therapeutics
Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases.
Iterum Therapeutics
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.
iDTx Systems
IDTx Systems develops aerosol therapy devices that focus on mechanical ventilation.
InHomeTherapy
InHomeTherapy is a provider of at-home based therapy and rehabilitation services for patients.
Iterative Scopes
Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Geminus Therapeutics
Geminus Therapeutics is developing best-in-class Artemisinin (ART714) for treating leukemia.
Owlstone Nanotech
OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
optiQGain
optiQGain is a innovative molecular level diagnostic company with imaging systems based on Quantum-Optics techniques.
Otolith Labs
First Therapeutic Device For The Treatment Of Vertigo.
Z.M.D. Medical
Z.M.D. Medical develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system.
Catalym
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Cyprium Therapeutics
Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
CND Life Sciences
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy.
COYOTE
Coyote Bioscience is the developer of point-of-care molecular diagnostics, pathogen detection, and life science tools.
CharlestonPharma,LLC
CharlestonPharma is focused on developing innovative therapeutic antibodies and related diagnostic tests for cancer patients.
Cancer Prevention Pharmaceuticals
Cancer Prevention Pharmaceuticals develops prevention therapies for people with elevated risk for cancer in the U.S.
CeleCor Therapeutics
CeleCor Therapeutics develops first-point contact treatments for segment elevated myocardial infarction.
Corteria Pharmaceuticals
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
Poppy
Poppy provides pathogen sensing and detection network that helps to protect places.
Precise Cardiology Limited
PRECISE is a unique detailed cloud based electrocardiogram (ECG) instant interpretation product aimed at GP's & medical diagnostic companies
PillGuard
PillGuard develops medication delivery devices that encourage patients to adhere to their medication.
PeptiStar
PeptiStar continually strives to develop novel manufacturing technologies to address needs in every stage of the peptide value chain.
Probably Genetic
Probably Genetic helps rare genetic disease patients.
PHDx Inc.
PHDx Inc. is a precision medicine diagnostic laboratory and services company.
Prevencio
Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease.
ProMIS Neurosciences
ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - C4 Therapeutics
Lightchain
Lightchain investment in Series B - C4 Therapeutics
Yonjin Venture
Yonjin Venture investment in Series B - C4 Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Debt Financing - C4 Therapeutics
Nextech Invest
Nextech Invest investment in Series B - C4 Therapeutics
Sphera Funds Management
Sphera Funds Management investment in Series B - C4 Therapeutics
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Series B - C4 Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series B - C4 Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - C4 Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - C4 Therapeutics
Official Site Inspections
http://www.c4therapeutics.com Semrush global rank: 4.94 M Semrush visits lastest month: 1.74 K
- Host name: 155.145.199.35.bc.googleusercontent.com
- IP address: 35.199.145.155
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "C4 Therapeutics"
C4 Therapeutics, Inc. | LinkedIn
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new …See details»
C4 Therapeutics Reports Full Year 2021 Financial Results and …
Feb 24, 2022 “The progress achieved across our organization in 2021, a year in which we dosed the first patient with our lead program while advancing additional candidates towards the clinic, …See details»
Press Releases – C4 Therapeutics, Inc.
Oct 31, 2024 WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to …See details»
C4 Therapeutics - Crunchbase Company Profile & Funding
Organization. C4 Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email …See details»
C4 Therapeutics - Overview, News & Similar companies - ZoomInfo
May 15, 2024 C4 Therapeutics contact info: Phone number: (617) 231-0700 Website: c4therapeutics.com What does C4 Therapeutics do? C4 Therapeutics is a clinical-stage …See details»
Release Details - ir.c4therapeutics.com
For more information, please visit www.c4therapeutics.com. About Cemsidomide Cemsidomide is an orally bioavailable MonoDAC ® degrader designed to be highly potent and selective …See details»
Protein degraded. Disease targeted. Lives transformed. - C4 …
CFT7455 Phase 1/2 Trial Progressing through Dose Escalation 7 R/R Multiple Myeloma Monotherapy N = ~30 Arm B1: R/R Multiple Myeloma Monotherapy N = 22See details»
C4 Therapeutics - MassBio
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target …See details»
C4 Therapeutics Announces 2024 Priorities and Extended Cash …
Jan 9, 2024 Company to Present at the 42 nd Annual J.P. Morgan Healthcare Conference on January 11. WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, …See details»
C4 Therapeutics Appoints Accomplished Oncology Executive Steve …
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing …See details»
C4 Therapeutics Announces Inducement Grant Under Nasdaq …
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing …See details»
C4 Therapeutics Announces 2024 Priorities and Extended Cash
Jan 9, 2024 Contacts:Investors: Courtney Solberg Senior Manager, Investor [email protected] Media: Loraine Spreen Senior Director, Corporate …See details»
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
Mar 16, 2022 Koppikar will also serve as chair of the Audit Committee and a member of the Organization, Leadership and Compensation Committee. Mr. Koppikar is the chief financial …See details»
C4 Therapeutics Raises $170 Million Financing to Bring Robust …
Jun 16, 2020 To learn more about C4 Therapeutics, visit www.C4Therapeutics.com. Contacts. Media Contact: Caroline Rufo, Ph.D. MacDougall 781-235-3060 [email protected] …See details»
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board …
C4 Therapeutics, Inc. Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience. Bruce Downey Remains a Member of the Board of Directors and …See details»
C4 Therapeutics - Craft
Oct 21, 2024 C4 Therapeutics has 5 employees at their 1 location and $20.76 m in annual revenue in FY 2023. See insights on C4 Therapeutics including office locations, competitors, …See details»
C4 Therapeutics Appoints Accomplished Oncology Executive Steve …
Nov 20, 2024 Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) …See details»
C4 Therapeutics Added to NASDAQ Biotechnology Index
Dec 17, 2021 To learn more about C4 Therapeutics, visit www.c4therapeutics.com. Investor Contact: Kendra Adams SVP, Communications & Investor Relations …See details»
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy …
Sep 8, 2024 C4T will host a webcast on Friday, September 13, 2024 at 12:00 pm ET. To join the webcast, please visit this link or the “Events & Presentations” page of the Investors section on …See details»